Please provide your email address to receive an email when new articles are posted on . In this video, Ursula A. Matulonis, MD, shares insight on the phase 3 KEYNOTE-B96 trial of pembrolizumab ...

Please provide your email address to receive an email when new articles are posted on . KEYNOTE-355 has already demonstrated PFS improvement, but “what we were all waiting for was the overall survival ...

In the 11 years since it was approved for the treatment of melanoma, pembrolizumab (Keytruda) has become the go-to for adjuvant or neoadjuvant therapy for advanced melanoma, despite the potential for ...

Promising trial results may be a breakthrough in treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer. In patients with muscle-invasive bladder cancer (MIBC) not eligible ...